PHASE 1

August 2023

• All the links have been checked and are properly working. 

​

June 2023:

• All the links have been checked and are working properly.

• The number of current clinical trials was updated accordingly.

• New links were added for the “Compound Name” for: STRO-002, Cofetuzumab pelidotin, and STI-6129.

​

April 2023

• Link for Cofetuzumab pelidotin’s “Company/Institution” has been updated with AbbVie's current pipeline webpage. All other links have been checked and are properly working.

• The number of current clinical trials was updated accordingly.

Points discussed during meeting:

• PF-06804103: This compound has no more active clinical trials; it is not found in the Pipeline on Pfizer’s website anymore either. It was decided to remove this compound in the Phase 1 page.

• SGN-CD228A: This compound’s Phase 1 study is “terminated”; however, it is still on the Pipeline under phase 1 on Seagen’s website. It was decided we should keep this compound in the Phase 1 page for some months.

​

February 2023

• All the links have been checked and were working properly. 

• The number of current clinical trials was updated accordingly.

• Link has been updated to show the company's pipeline page for A-166. 

• Compound name for MorAb-202 has been updated to Farletuzumab Ecteribulin (MorAb-202). 

• New compound, EBC-129, has been added. 
   

December 2022 

All the links have been checked and were working properly. The number of clinical trials in Phase 1 is currently reflected on the website. Recent updates to phase 1 clinical trials include compounds completing phase 1, progressing to phase 2, and phase 3. 

• ARX-788: has six trials in progress: 1 phase 1 trial, 5 phase 2 trials, and 1 phase 3 trial.   

• XMT-153:  named upifitamab rilsodotin, has 2 phase 1 trials, 1 phase 2 trial and 1 phase 3 trial.  

• MORAb-202: has 3 phase 2 trials, and 1 phase 1 trial.   

• MRG003: has 5 phase 2 trials, and 1 phase 1 trial.  

• RC-88: has 1 phase 2 trial, and 2 phase 1 trials.  

• STI-6129:  3 Phase 2 trials, and 5 phase 1 trials.   

​

September 2022

• During September copyright notices were posted on the top and bottom of this page. Date of the last update has been edited.  

• ARX-788 has 6 US clinical trials ( https://clinicaltrials.gov/ct2/results?cond=ARX788&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=), and has been added to the Phase 3 webpage.

• XMT-1536 (upifitamab rilsodotin)  has a US Active Phase 3 trial ( https://clinicaltrials.gov/ct2/show/NCT05329545?recrs=abdf&cond=XMT-1536&draw=2&rank=2) has been added to the Phase 3 webpage.  

• MORab-202 (Farletuzumab  Ecteribulin) has a US Active Phase 2 trial (https://www.clinicaltrials.gov/ct2/show/NCT04300556?recrs=abdf&cond=MORAb-202&draw=2&rank=2) and has been added to the Phase 2 webpage.

• MRG003 has 5 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/resultscond=mrg003&term=&cntry=&state=&city=&dist=&Search=Search) and has been added to the Phase 2 webpage.

• A-166 has 2 US Active Phase 2 trials (https://clinicaltrials.gov/ct2/show/NCT05346328?cond=A-166&draw=2&rank=3) and has been added to the Phase 2 webpage.